This is according to results of a clinical trial published on Thursday the journal The Lancet and had already been advanced in different oncology conferences. Existing treatments for advanced tumors not only serve to combat the disease but to improve the quality of life of patients.
But 10 years ago that did not appear a new medication without combined, have an impact on survival of patients with this type of tumor. The study (Phase III, designed to measure efficacy and toxicity compared to current treatments) has been coordinated by the breast cancer group at the Institute of Oncology, Vall d'Hebron and was attended by 762 women from over 130 health centers in 12 countries previously treated (between two and five cycles of chemotherapy with antracina or taxane). A 508 was administered eribulin. In the remaining 254 were given the best treatment that was considered in each case to treat the tumor, whether the existing chemotherapy drugs, an approach to therapy hormonal or against molecular targets. The result was that people treated with eribulin achieved a median survival of 13.6 months compared with 10.5 in the other treatments.
Regarding side effects, 54% of patients treated with this drug were asthenia or fatigue (compared with 30% of another group of women) and 52% neutropenia, white blood cells drop-(by 30% in the remaining patients). The most common problem was peripheral neuropathy (pain and loss of muscle soreness), which led to discontinuation in 5% of cases. "The eribulin has proven effective in all breast cancers," said Javier Cortes director of the breast cancer unit of the Vall d'Hebron and first author of the article. Cortés explained that this drug has a dual action mechanism. "On one hand prevents the division of tumor cells, which is already done other chemotherapy treatments, but also the eribulin binds to tubulin (a protein essential for the cell's internal skeleton) and produces aggregates that kill the cell tumor, "says the researcher of the Catalan center. "This study suggests that phase III used as single agent, this drug could prove a new standard of therapy for women with severe pre-treatment to breast cancer metastasis" According to the authors of the work. The FDA (the national drug control in the U.S.) has authorized the sale of this product, which sells the Japanese laboratory under the brand Eisai Halav. "Europe is probably the agency approved the drug in June," says oncologist Catalan.
there is another medication now approved tumor arising from the seabed. This is Yondelis (English company PharmaMar) indicated to treat sarcomas and ovarian cancer
source: mejorsalud
0 comments:
Post a Comment